Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study.

Published

Journal Article

To examine a 1-year follow-up of a 4-month, controlled clinical trial of exercise and antidepressant medication in patients with major depressive disorder (MDD).In the original study, 202 sedentary adults with MDD were randomized to: a) supervised exercise; b) home-based exercise; c) sertraline; or d) placebo pill. We examined two outcomes measured at 1-year follow-up (i.e., 16 months post randomization): 1) continuous Hamilton Depression Rating Scale score; and 2) MDD status (depressed; partial remission; full remission) in 172 available participants (85% of the original cohort). Regression analyses were performed to examine the effects of treatment group assignment, as well as follow-up antidepressant medication use and self-reported exercise (Godin Leisure-Time Exercise Questionnaire), on the two outcomes.In the original study, patients receiving exercise achieved similar benefits compared with those receiving sertraline. At the time of the 1-year follow-up, rates of MDD remission increased from 46% at post treatment to 66% for participants available for follow-up. Neither initial treatment group assignment nor antidepressant medication use during the follow-up period were significant predictors of MDD remission at 1 year. However, regular exercise during the follow-up period predicted both Hamilton Depression Rating Scale scores and MDD diagnosis at 1 year. This relationship was curvilinear, with the association concentrated between 0 minute and 180 minutes of weekly exercise.The effects of aerobic exercise on MDD remission seem to be similar to sertraline after 4 months of treatment; exercise during the follow-up period seems to extend the short-term benefits of exercise and may augment the benefits of antidepressant use.clinicaltrials.gov Identifier: NCT00331305.

Full Text

Duke Authors

Cited Authors

  • Hoffman, BM; Babyak, MA; Craighead, WE; Sherwood, A; Doraiswamy, PM; Coons, MJ; Blumenthal, JA

Published Date

  • February 2011

Published In

Volume / Issue

  • 73 / 2

Start / End Page

  • 127 - 133

PubMed ID

  • 21148807

Pubmed Central ID

  • 21148807

Electronic International Standard Serial Number (EISSN)

  • 1534-7796

International Standard Serial Number (ISSN)

  • 0033-3174

Digital Object Identifier (DOI)

  • 10.1097/PSY.0b013e31820433a5

Language

  • eng